Lck-IN-1 is a potent lymphocyte protein tyrosine kinase (Lck) inhibitor extracted from patent WO2007013673A1, example 48[1].
ETP-47799 is a potent and CDK8-/CDK19-selective cyclin-dependent kinase inhibtor (CDK8/19 IC50 = 2.9/14.1 nM; CDK1/5/9 IC50 = 275/239/124 nM; CDK2/4/6/7 IC50 >1 μM; GSK3β IC50 = 3.14 μM) with additional potency against PDGFRα (IC50 = 3.5 nM). ETP-47799 ( 0.4 μM or 1.1 μM) induces and stabilizes the naive state of murine and human pluripotent stem cells (PSCs) with better efficiency than the commonly used MEK/GSK3 inhibitor cocktail (1μM PD0325901, 1.5μM CHIR 99021).
[1] Kazuo Nakai, et al. Fused heterocycles as lck inhibitors. WO2007013673A1.